517 related articles for article (PubMed ID: 33690617)
21. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer.
Wu C; Jin X; Yang J; Yang Y; He Y; Ding L; Pan Y; Chen S; Jiang J; Huang H
Oncotarget; 2016 Jan; 7(3):3440-52. PubMed ID: 26657505
[TBL] [Abstract][Full Text] [Related]
22. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition.
Amatangelo MD; Garipov A; Li H; Conejo-Garcia JR; Speicher DW; Zhang R
Cell Cycle; 2013 Jul; 12(13):2113-9. PubMed ID: 23759589
[TBL] [Abstract][Full Text] [Related]
23. Verification of EZH2 as a druggable target in metastatic uveal melanoma.
Jin B; Zhang P; Zou H; Ye H; Wang Y; Zhang J; Yang H; Pan J
Mol Cancer; 2020 Mar; 19(1):52. PubMed ID: 32127003
[TBL] [Abstract][Full Text] [Related]
24.
Guo J; Zhu H; Li Q; Dong J; Xiong W; Yu K
Aging (Albany NY); 2021 Apr; 13(8):11665-11677. PubMed ID: 33879635
[TBL] [Abstract][Full Text] [Related]
25. Anti-cancer Effects of Curcumin on Myelodysplastic Syndrome through the Inhibition of Enhancer of Zeste Homolog-2 (EZH2).
Ma L; Zhang X; Wang Z; Huang L; Meng F; Hu L; Chen Y; Wei J
Curr Cancer Drug Targets; 2019; 19(9):729-741. PubMed ID: 30747066
[TBL] [Abstract][Full Text] [Related]
26. Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.
Song X; Gao T; Wang N; Feng Q; You X; Ye T; Lei Q; Zhu Y; Xiong M; Xia Y; Yang F; Shi Y; Wei Y; Zhang L; Yu L
Sci Rep; 2016 Feb; 6():20864. PubMed ID: 26868841
[TBL] [Abstract][Full Text] [Related]
27. Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.
Lue JK; Prabhu SA; Liu Y; Gonzalez Y; Verma A; Mundi PS; Abshiru N; Camarillo JM; Mehta S; Chen EI; Qiao C; Nandakumar R; Cremers S; Kelleher NL; Elemento O; Amengual JE
Clin Cancer Res; 2019 Sep; 25(17):5271-5283. PubMed ID: 30979734
[TBL] [Abstract][Full Text] [Related]
28. S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells.
Liu TP; Lo HL; Wei LS; Hsiao HH; Yang PM
Anticancer Drugs; 2015 Feb; 26(2):139-47. PubMed ID: 25203626
[TBL] [Abstract][Full Text] [Related]
29. EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications.
Li Z; Takenobu H; Setyawati AN; Akita N; Haruta M; Satoh S; Shinno Y; Chikaraishi K; Mukae K; Akter J; Sugino RP; Nakazawa A; Nakagawara A; Aburatani H; Ohira M; Kamijo T
Oncogene; 2018 May; 37(20):2714-2727. PubMed ID: 29507419
[TBL] [Abstract][Full Text] [Related]
30. LncRNA XIST facilitates cell growth, migration and invasion via modulating H3 histone methylation of DKK1 in neuroblastoma.
Zhang J; Li WY; Yang Y; Yan LZ; Zhang SY; He J; Wang JX
Cell Cycle; 2019 Aug; 18(16):1882-1892. PubMed ID: 31208278
[TBL] [Abstract][Full Text] [Related]
31. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
[No Abstract] [Full Text] [Related]
32. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway.
Zhang P; Yang X; Ma X; Ingram DR; Lazar AJ; Torres KE; Pollock RE
Mol Cancer; 2015 Mar; 14():55. PubMed ID: 25890085
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of (E)-1,2-diphenylethene-based EZH2 inhibitors.
He H; Hu X; Teng F; Liu Z; Zhang Q; Feng Z; Feng Q; Yu L
Bioorg Med Chem Lett; 2020 Mar; 30(5):126957. PubMed ID: 31959420
[TBL] [Abstract][Full Text] [Related]
34. Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer.
Yamada L; Saito M; Thar Min AK; Saito K; Ashizawa M; Kase K; Nakajima S; Onozawa H; Okayama H; Endo H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Kono K
Gastric Cancer; 2021 Jan; 24(1):60-71. PubMed ID: 32506298
[TBL] [Abstract][Full Text] [Related]
35. Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells.
Zeng D; Liu M; Pan J
Oncotarget; 2017 Jan; 8(2):3396-3411. PubMed ID: 27926488
[TBL] [Abstract][Full Text] [Related]
36. Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts.
Stafman LL; Williams AP; Marayati R; Aye JM; Markert HR; Garner EF; Quinn CH; Lallani SB; Stewart JE; Yoon KJ; Whelan K; Beierle EA
Sci Rep; 2019 Sep; 9(1):13259. PubMed ID: 31519958
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential.
Sun R; Shen J; Gao Y; Zhou Y; Yu Z; Hornicek F; Kan Q; Duan Z
Oncotarget; 2016 Jun; 7(25):38333-38346. PubMed ID: 27223261
[TBL] [Abstract][Full Text] [Related]
38. EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.
Wang C; Liu Z; Woo CW; Li Z; Wang L; Wei JS; Marquez VE; Bates SE; Jin Q; Khan J; Ge K; Thiele CJ
Cancer Res; 2012 Jan; 72(1):315-24. PubMed ID: 22068036
[TBL] [Abstract][Full Text] [Related]
39. [Effects of Histone Methyltransferase Inhibitors on the Survival, Apoptosis and Cell Cycle of Raji Cells].
Xiao LR; Hou C; Zheng SJ; Guo B; Chen DN; Yan NH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 May; 50(3):305-310. PubMed ID: 31631594
[TBL] [Abstract][Full Text] [Related]
40. Review: Targeting EZH2 in neuroblastoma.
Gao J; Fosbrook C; Gibson J; Underwood TJ; Gray JC; Walters ZS
Cancer Treat Rev; 2023 Sep; 119():102600. PubMed ID: 37467626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
